ProStrakan's early-2008 sales exceed projections

Scottish drugmaker ProStrakan says that trading in the first four months of 2008 has been at the upper end of management expectations, with total product revenues increasing 38% over the like period in 2007, with the stronger euro accounting for 8% of that growth.

In its interim management statement, the company noted that it saw continued growth of its pan-European products. Combined sales of Tostran (testosterone gel), Rectogesic (glyceryl trinitrate ointment), sold as Cellgesic in the USA, and Xomolix (droperidol), which is indicated as a pre-medication for anesthesia, nausea after anesthesia or for the sedation of agitated patients, rose 75%. The strength of the euro accounted for 16% of this uplift.